VSTM240719P5000
- 1.70
- -0.75-30.61%
Verastem Newsroom
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), HilleVax, Inc (HLVX) and Schrodinger (SDGR)
Verastem Analyst Ratings
Truist Securities Maintains Buy on Verastem, Lowers Price Target to $18
Truist Securities Adjusts Price Target on Verastem to $18 From $34, Notes Recent Stock Pull Back; Maintains Buy Rating
Verastem Analyst Ratings
BTIG Sticks to Its Buy Rating for Verastem (VSTM)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pro Medicus Limited (OtherPMCUF), AdaptHealth (AHCO) and Verastem (VSTM)
Verastem (VSTM) Receives a Buy From Truist Financial
RBC Halves Price Target on Verastem to $16 From $32, Maintains Outperform Rating, Speculative Risk Qualifier
Verastem Analyst Ratings
Buy Rating Affirmed for Verastem Based on Promising Clinical Results and Strategic Regulatory Advances
Buy Rating Affirmed for Verastem Amidst Promising Clinical Data and Market Expansion Potential
Buy Rating on Verastem: Promising RAMP 201 Study Outcomes and Favorable Investment Potential
Buy Rating Affirmed for Verastem Amid Positive Developments and Strong Financial Position
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), ANI Pharmaceuticals (ANIP) and Argenx Se (ARGX)
Verastem Analyst Ratings
Buy Rating on Verastem: Promising Pipeline and Regulatory Milestones Drive Positive Outlook
RBC Capital Sticks to Their Buy Rating for Verastem (VSTM)
Verastem Inc. Poised for Growth: Buy Rating Affirmed on Clinical and Regulatory Milestones
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Laboratory (LH) and Longboard Pharmaceuticals (LBPH)